IDEAS home Printed from https://ideas.repec.org/p/ohe/monogr/000453.html
   My bibliography  Save this paper

Risk and Return in the Pharmaceutical Industry

Author

Listed:
  • Nick Marchant

Abstract

This book has been built up from the papers delivered at the Office of Health Economics conference which took place at the Langham Hilton Hotel, London, on 5 December 1996. The speakers assembled for this symposium represent important contributors to the economic analysis of the risks inherent in pharmaceutical research and development (R&D) and the returns achieved by it. Together these authors bring to this analysis a unique combination of academic rigour and detailed knowledge of industry practice. The result is a series of telling insights into the peculiar characteristics of the risk/return trade-offs intrinsic to R&D in the pharmaceutical industry.

Suggested Citation

  • Nick Marchant, 1999. "Risk and Return in the Pharmaceutical Industry," Monograph 000453, Office of Health Economics.
    • Handle: RePEc:ohe:monogr:000453
    as

    Download full text from publisher

    File URL: https://www.ohe.org/publications/risk-and-return-pharmaceutical-industry/attachment-256-1999_risk_and_return_sussex/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Cockburn, Iain & Henderson, Rebecca, 1994. "Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 3(3), pages 481-519, Fall.
    2. repec:bla:jemstr:v:3:y:1994:i:3:p:481-519:a is not listed on IDEAS
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Gerullis, Maria & Heckelei, Thomas & Rasch, Sebastian, 2020. "Towards understanding the governance of varietal and genetic diversity," 60th Annual Conference, Halle/ Saale, Germany, September 23-25, 2020 305589, German Association of Agricultural Economists (GEWISOLA).

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Sternitzke, Christian, 2013. "An exploratory analysis of patent fencing in pharmaceuticals: The case of PDE5 inhibitors," Research Policy, Elsevier, vol. 42(2), pages 542-551.
    2. Philippe Aghion & Antoine Dechezleprêtre & David Hémous & Ralf Martin & John Van Reenen, 2016. "Carbon Taxes, Path Dependency, and Directed Technical Change: Evidence from the Auto Industry," Journal of Political Economy, University of Chicago Press, vol. 124(1), pages 1-51.
    3. Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
    4. Nicholas Bloom & Mark Schankerman & John Van Reenen, 2013. "Identifying Technology Spillovers and Product Market Rivalry," Econometrica, Econometric Society, vol. 81(4), pages 1347-1393, July.
    5. Joshua S. Gans & David H. Hsu & Scott Stern, 2002. "When Does Start-Up Innovation Spur the Gale of Creative Destruction?," RAND Journal of Economics, The RAND Corporation, vol. 33(4), pages 571-586, Winter.
    6. Linda R. Cohen & Jun Ishii, 2005. "Competition, Innovation and Racing for Priority at the U.S. Patent and Trademark Office," Working Papers 050604, University of California-Irvine, Department of Economics.
    7. Joshua Gans & Scott Stern, 2003. "When does funding research by smaller firms bear fruit?: Evidence from the SBIR program," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 12(4), pages 361-384.
    8. Schwartz, Eduardo S., 2002. "Patents and R& D as Real Options," University of California at Los Angeles, Anderson Graduate School of Management qt86b1n43k, Anderson Graduate School of Management, UCLA.
    9. Scherer, F. M., 2007. "Pharmaceutical Innovation," Working Paper Series rwp07-004, Harvard University, John F. Kennedy School of Government.
    10. Garcés-Ayerbe, Concepción & Cañón-de-Francia, Joaquín, 2017. "The Relevance of Complementarities in the Study of the Economic Consequences of Environmental Proactivity: Analysis of the Moderating Effect of Innovation Efforts," Ecological Economics, Elsevier, vol. 142(C), pages 21-30.
    11. Zizzo, Daniel John, 2002. "Racing with uncertainty: a patent race experiment," International Journal of Industrial Organization, Elsevier, vol. 20(6), pages 877-902, June.
    12. Austin, David H., 2000. "Patents, Spillovers, and Competition in Biotechnology," Discussion Papers 10808, Resources for the Future.
    13. Julian Romero & Yaroslav Rosokha, 2023. "Mixed Strategies in the Indefinitely Repeated Prisoner's Dilemma," Econometrica, Econometric Society, vol. 91(6), pages 2295-2331, November.
    14. James Bessen, 2010. "Communicating Technical Knowledge," Working Papers 1001, Research on Innovation.
    15. David P. Baron, 2020. "Vertical differentiation, product innovation, and dynamic competition," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 29(3), pages 635-662, July.
    16. Yang, Hongyan & Steensma, H. Kevin, 2014. "When do firms rely on their knowledge spillover recipients for guidance in exploring unfamiliar knowledge?," Research Policy, Elsevier, vol. 43(9), pages 1496-1507.
    17. Yuk Ying Chang & Martin Young, 2015. "Dissipative Competition: Evidence from a Quasi-Natural Experiment," International Review of Finance, International Review of Finance Ltd., vol. 15(2), pages 169-198, June.
    18. Michael K. Fung, 2006. "R&D, knowledge spillovers and stock volatility," Accounting and Finance, Accounting and Finance Association of Australia and New Zealand, vol. 46(1), pages 107-124, March.
    19. Aurora Teixeira & Joana Costa, 2006. "What Type of Firm Forges Closer Innovation Linkages with Portuguese Universities?," Notas Económicas, Faculty of Economics, University of Coimbra, issue 24, pages 22-47, December.
    20. Filson, Darren & Gretz, Richard T., 2004. "Strategic innovation and technology adoption in an evolving industry," Journal of Monetary Economics, Elsevier, vol. 51(1), pages 89-121, January.

    More about this item

    Keywords

    Risk and Return in the Pharmaceutical Industry;

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:monogr:000453. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Publications Manager (email available below). General contact details of provider: https://edirc.repec.org/data/ohecouk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.